13th Nov 2019 16:10
(Alliance News) - BioPharma Credit PLC said on Wednesday it has entered into two separate agreements to invest USD52.5 million now and up to additional USD32.5 million over the next 12 months.
The life sciences debt investor said on Tuesday last week it entered into a definitive senior secured term loan agreement for up to USD70.0 million with Epizyme Inc.
BioPharma said Epizyme, which develops novel epigenetic therapies, has a current market capitalization of approximately USD1.4 billion.
The company said the investment was made alongside BioPharma-V private fund.
BioPharma said on Monday it has also entered into a definitive senior secured term loan agreement for up to USD100 million with Akebia Inc.
The company said Akebia, which is focused on the development and commercialization of therapeutics for people living with kidney disease, has a current market capitalization of approximately USD460 million. The investment was also made through BioPharma-V, the company noted.
The company said both loans will mature in November 2024.
BioPharma shares were up 0.8% in London at 1.01 pence each Wednesday.
By Loreta Juodagalvyte; [email protected]
Copyright 2019 Alliance News Limited. All Rights Reserved.
Related Shares:
Biopharma Cred.